ImmunityBio converts from Immunomedics | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ImmunityBio converts from Immunomedics

An SI Board Since February 2023

Posts	SubjectMarks	Bans	Symbol
1516	51	0	IBRX

Emcee: TinfoilHat	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
660	Nice close	erippetoe	-	9/26/2024
659	At first glance a potential new investor who hadn’t done their dd might be hesit	Redman1234	5	9/22/2024
658	SeekingAlpha latest article. ImmunityBio: Anktiva Launch, Good Data, Low Cash,	Redman1234	-	9/22/2024
657	It's pretty amazing how far along Chatgpt has come in the past year or so. I	ghettogoulash	-	9/18/2024
656	So an average of 6 million in sales approximately for 2024 is probably not going	zagnut1	-	9/17/2024
655	"Dude, IBRX is burning $130M per quarter. What's your point?" The	End2War	2	9/17/2024
654	Dude, IBRX is burning $130M per quarter. What's your point? Also, I notice	ghettogoulash	2	9/17/2024
653	We strongly suggest listening to the HC Wainright presentation on the ImmunityBi	bobbseytwins2001	4	9/16/2024
652	Can I recommend a post twice?	mannamal	-	9/16/2024
651	I asked my wife to update her opinion of my biotech investment strategy based on	jargonweary	4	9/16/2024
650	I asked Chat-GPT to update its analysis of next quarter Anktiva sales based on A	End2War	3	9/16/2024
649	I fed the Chat GPT projections to Google's advanced AI called "Gemini A	End2War	3	9/13/2024
648	I got access this morning to Chat GPT 1.0, a new supposedly better GPT for reaso	End2War	2	9/13/2024
647	I agree with your assessment as far as it goes in regards to buyout as well as s	Redman1234	1	9/13/2024
646	Your AI helper laid out the Anktiva scenario very well. We see nothing to argue	bobbseytwins2001	3	9/12/2024
645	I personally don't think that IBRX is anywhere near a buyout at this stage o	End2War	5	9/12/2024
644	While a partnership with Merck would be the preferred route, I don’t why a deal	Redman1234	-	9/12/2024
643	Tinfoil, I'm thinking the other three arms are fully enrolled, except for Co	ghettogoulash	-	9/11/2024
642	Definitely time for some news, whether partnership or outlicensing or AA filing	TinfoilHat	5	9/10/2024
641	I would love to have a 2nd IBRX PR before closing with either Fast Track or Brea	Redman1234	1	9/9/2024
640	SMMT trials done in China. The plus about China is they have a large and ready p	Redman1234	3	9/9/2024
639	SMMT...up 72% with similar news at conference Summit’s checkpoint inhibitor tru	urslor	-	9/9/2024
638	more validation that anktiva is a real drug and the market responds with a ho hu	urslor	1	9/9/2024
637	ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell	zagnut1	5	9/9/2024
636	Business wire sept 9 ImmunityBio Presents Positive Long-Term Overall Survival Da	zagnut1	2	9/9/2024

Go to reply# or date (mm/dd/yy):